NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Type 2 Diabetes
Date of first enrollment	27/07/2006
Target sample size	236
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : Vildagliptin INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : Oral

Outcome(s)

Primary Outcome	Primary Outcomes: Change from baseline on HbA1c at 12 weeks Secondary Outcomes: Change from baseline on fasting plasma glucose at 12 weeks; Change from baseline on HOMA-veta at 12 weeks; Change from baseline on HOMA-R at 12 weeks; Change from baseline in body weight at 12 weeks; Change from baseline on fasting lipids at 12 weeks
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Both
Include criteria	Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both Inclusion Criteria: - Diagnosis of type 2 diabetes - Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels - Outpatients Exclusion Criteria: - Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes - Significant cardiovascular complications - Significant diabetic complications Other protocol-defined inclusion/exclusion criteria may apply
Exclude criteria